FDA grants approval to Ipsen for ultra-rare bone disease drug
Ipsen heralded the greenlight of the treatment, which reduces new, abnormal bone formation in soft and connective tissues for people living with FOP.
United States Howard Mayer European Commission Drug Administration Metabolic Drugs Advisory Committee Ipsen Pharmaceutical
Source: mmm-online.com